Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer - a pilot study

Folia Histochemica et Cytobiologica

Volumn 50, Issue 1, 2012, Pages 80-86

  Krawczyk, Pawel ^a   Wojas Krawczyk, Kamila ^a   Mlak, Radoslaw ^a   Kucharczyk, Tomasz ^a,b   Biernacka, Beata ^a   Milanowski, Janusz ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

ERCC1; Non small cell lung cancer; Platinum based chemotherapy; Single nucleotide polymorphism

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOSINE; DNA; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; PACLITAXEL; TYROSINE;

ADULT; ADVANCED CANCER; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ISOLATION; DRUG TREATMENT FAILURE; ERCC1 GENE; FEMALE; GENE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL LYMPHOCYTE; PILOT STUDY; POLYMERASE CHAIN REACTION; PREDICTION; PREDICTIVE VALUE; PROBABILITY; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 84860277658     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2012.0011     Document Type: Article

References (15)

1. Jassem J, Biernat W, Drosik K et al. Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma. Pneumonol Alergol Pol. 2010;78:418-431.
2. NSCLC Meta-Analysis Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer. A systemic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617-4625.
3. Vilmar A, Sorensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of nonsmall cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009;64:131-139.
4. Olaussen K, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;335:983-981.
5. Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expression but not EGFR are predictive of shorter survival in advanced non-small cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17:1818--1825.
6. Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small cell lung cancer. Ann Oncol. 2004;15:1194-1203.
7. Takenaka T, Yano T, Kiyohara C et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer. 2010;67:101-107.
8. Gao R, Reece K, Sissung T, Reed E, Price DK, Figg WD. The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutat Res. 2011;708:21-27.
9. Zheng Z, Chen T, Li X et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007; 356: 800-808.
10. Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;1: 2747-2754.
11. Ryu JS, Hong YC, Han HS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer. 2004;44:311-316.
12. Kalikaki A, Kanaki M, Vassalou H et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small cell lung cancer. Clin Lung Cancer. 2009;10:118-123.
13. Taron M, Alberola V, Lopez Vivanco G et al. Excision crosscomplementing group 1 (ERCC1) single nucleotide polymorphisms (SNPs) and survival in cisplatin (cis)/docetaxel (doc)-treated stage IV non-small cell lung cancer (NSCLC) patients (p): a Spanish Lung Cancer Group study. J Clin Oncol. 2006;24:7053.
14. Tibaldi C, Giovannetti E, Vasile E et al. Correlation of CDA, ERCC1 and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced nonsmall cell lung cancer patients. Clin Cancer Res. 2008; 14:1797-1803.
15. Zhou C, Ren S, Zhou S et al. Genotyping single-nucleotide polymorphisms (SNPs) in ERCC1 and XRCC3 genes for efficacy in chemotherapy of non-small cell lung cancer (NSCLC). J Clin Oncol. 2008;26:8098.